Skip to Main Content

Paper Details

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Ann Oncol
120
2021
Author NameAffiliation
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School
Wells A MessersmithUniversity of Colorado Cancer Center
Linda T Vahdat
Joshua M LangUniversity of Wisconsin Carbone Cancer Center
Allyson J Ocean
  • 1 - 5

Datasets

Release 1.2